Immune thrombocytopenia (ITP):
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Bremen ; London ; Boston
UNI-MED Verlag AG
2022
|
| Ausgabe: | 3rd edition |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltstext Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | 204 Seiten Illustrationen 25 cm, 495 g |
| ISBN: | 9783837416244 3837416240 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV048577021 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 221123s2022 gw a||| |||| 00||| eng d | ||
| 015 | |a 22,N21 |2 dnb | ||
| 015 | |a 22,A27 |2 dnb | ||
| 016 | 7 | |a 1258091410 |2 DE-101 | |
| 020 | |a 9783837416244 |c Festeinband : EUR 44.80 (DE), EUR 46.10 (AT), CHF 74.00 (freier Preis) |9 978-3-8374-1624-4 | ||
| 020 | |a 3837416240 |9 3-8374-1624-0 | ||
| 024 | 3 | |a 9783837416244 | |
| 035 | |a (OCoLC)1319834906 | ||
| 035 | |a (DE-599)DNB1258091410 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-HB | ||
| 049 | |a DE-19 | ||
| 082 | 0 | 4 | |a 616.15 |2 23/ger |
| 084 | |a YC 2922 |0 (DE-625)153205:12928 |2 rvk | ||
| 100 | 1 | |a Kühne, Thomas |e Verfasser |0 (DE-588)1037169956 |4 aut | |
| 245 | 1 | 0 | |a Immune thrombocytopenia (ITP) |c Thomas Kühne ; in collaboration with Carlo L. Balduini [und 25 andere] |
| 250 | |a 3rd edition | ||
| 264 | 1 | |a Bremen ; London ; Boston |b UNI-MED Verlag AG |c 2022 | |
| 300 | |a 204 Seiten |b Illustrationen |c 25 cm, 495 g | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 650 | 0 | 7 | |a Essenzielle Thrombozytopenie |0 (DE-588)4070972-3 |2 gnd |9 rswk-swf |
| 653 | |a Immune Thrombocytopenia | ||
| 653 | |a ITP | ||
| 653 | |a thrombocytopenic purpura | ||
| 653 | |a Immune Thrombocytopenia;TIP;thrombocytopenic purpura | ||
| 689 | 0 | 0 | |a Essenzielle Thrombozytopenie |0 (DE-588)4070972-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 710 | 2 | |a UNI-MED Verlag AG |0 (DE-588)1065561733 |4 pbl | |
| 780 | 0 | 0 | |i Vorangegangen ist |z 9783837413960 |
| 856 | 4 | 2 | |m X:MVB |q text/html |u http://deposit.dnb.de/cgi-bin/dokserv?id=5ef5396f02c440b3a3b82923702711f2&prov=M&dok_var=1&dok_ext=htm |3 Inhaltstext |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u https://d-nb.info/1258091410/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033952989&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033952989 | ||
Datensatz im Suchindex
| _version_ | 1804184604093972480 |
|---|---|
| adam_text | 14
CONTENTS
CONTENTS
INTRODUCTION
18
HISTORY
OF
ITP
21
2.1.
INTRODUCTION:
WHAT
IS
THROMBOCYTOPENIC
BLEEDING?
.....................................................................
21
2.2.
HISTORY
OF
BLEEDING
.........................................................................................................................
22
2.3.
HISTORY
OF
THE
PATHOGENESIS
OF
ITP
.................................................................................................
23
2.4.
HISTORY
OF
MANAGEMENT
OF
PATIENTS
WITH
ITP
................................................................................
23
2.5.
THE
THERAPEUTIC
TRANSLATION
OF
MG
TO
OTHER
AUTOIMMUNE
DISORDERS
WITH
SIMILAR
PATHOPHYSIOLOGY
AS
IN
ITP
.............................................................................................
25
2.6.
STIMULATION
OF
PLATELET
PRODUCTION
BY
MEGAKARYOCYTES
.............................................................
26
2.7.
RECENT
DEVELOPMENT
OF
CLINICAL
RESEARCH
OF
ITP
AND
NEW
ASPECTS
OF
PLATELETS
THEMSELVES
...
27
BASIC
IMMUNOLOGY
OF
ITP
30
3.1.
T
CELL
AND
CYTOKINE ABNORMALITIES
IN
ITP
.......................................................................................
30
3.2.
B
CELL
ABNORMALITIES
.........................................................................................................................
31
3.3.
DENDRITIC
CELLS
(DC)
IN
ITP
..............................................................................................................
31
3.4.
ENVIRONMENTAL
FACTORS
IN
ITP
...........................................................................................................
32
3.5.
ALTERNATIVE
MODES
OF
THROMBOCYTOPENIA
IN
ITP
............................................................................
33
3.6.
CONCLUSIONS
....................................................................................................................................
33
JI
MEGAKARYOPOIESIS
IN
ITP
36
4.1.
OVERVIEW
OF
NORMAL
THROMBOPOIESIS
.............................................................................................
36
4.2.
THROMBOPOIESIS
IN
ITP:
EVIDENCE
FOR
ACCELERATED
PLATELET
DESTRUCTION
......................................
38
4.3.
THROMBOPOIESIS
IN
ITP:
EVIDENCE
FOR
IMPAIRED
PLATELET
PRODUCTION
...........................................
39
4.4.
MEGAKARYOPOIESIS
IN
ITP:
EVIDENCE
FOR
DIRECT
ROLES
OF
MEGAKARYOCYTES
.....................................40
GENETICS
OF
ITP
45
5.1.
CHALLENGES
IN
DEFINING
A
GENETIC
ETIOLOGY
OF
ITP
..........................................................................
45
5.2.
GERMLINE
SINGLE-NUCLEOTIDE
VARIANT
(5NV)
CANDIDATE
GENE
APPROACH
........................................
45
5.3.
FAMILIAL
ITP
.......................................................................................................................................
45
5.4.
GENOME-WIDE
ASSOCIATION
STUDIES
(GWAS)
...................................................................................46
5.5.
FUTURE
DIRECTIONS
............................................................................................................................
47
U
DIFFERENTIAL
DIAGNOSIS
OF
ITP:
INHERITED
THROMBOCYTOPENIAS 48
6.1.
INHERITED
THROMBOCYTOPENIAS
........................................................................................................48
6.1.1.
CLINICAL
AND
LABORATORY
PECULIARITIES
OF
INHERITED
THROMBOCYTOPENIAS
..............................................
48
6.1.2.
WHEN
TO
SUSPECT
INHERITED
THROMBOCYTOPENIAS
................................................................................
54
6.2.
DIFFERENTIAL
DIAGNOSIS
BETWEEN
ITP
AND
INHERITED
THROMBOCYTOPENIAS
.....................................
55
6.3.
HOW
TO
CONFIRM
THE
SUSPICION
OF
INHERITED
THROMBOCYTOPENIA
...................................................
57
J|
SECONDARY
ITP
59
7.1.
DEFINITION
AND
LIMITATION
................................................................................................................
59
7.2.
ETIOLOGY
............................................................................................................................................
59
7.3.
DIAGNOSTIC
WORKFLOW
.......................................................................................................................
60
CONTENTS
15
7.4.
GENETIC
PANEL
...................................................................................................................................
62
7.5.
ADULT
VERSUS
CHILDREN
.....................................................................................................................
62
7.6.
CONCLUSIONS
.....................................................................................................................................
64
STANDARDIZATION
OF
DEFINITIONS,
TERMINOLOGY
AND
OUTCOME
CRITERIA:
A
COMMON
LANGUAGE
IN
ITP
67
8.1.
CRITERIA
ADOPTED
BY
THE
IWG
TO
HARMONIZE
TERMINOLOGY
AND
DEFINITIONS
IN
ITP
.........................
68
8.2.
PRIMARY
AND
SECONDARY
ITP
AND
DIAGNOSTIC
PLATELET
COUNT
THRESHOLD
........................................
68
8.3.
DEFINITION
OF
THE
DIFFERENT
PHASES
AND
SEVERITY
OF
THE
DISEASE
....................................................
69
8.4.
THERAPEUTIC
GOALS
............................................................................................................................
70
8.5.
DEFINITION
OF
RESPONSE
....................................................................................................................
71
8.6.
REFRACTORY
ITP:
DEFINITION,
THERAPEUTIC
GOALS
AND
RESPONSE
ASSESSMENT
.....................................
73
8.7.
CLINICAL
TRIAL-ADAPTED
CRITERIA
FOR
ELIGIBILITY
AND
OUTCOME
ASSESSMENT
........................................
75
8.8.
APPLICATION
OF
2009
IWG
PROPOSALS
IN
REAL-WORD
AND
NEED
FOR
REVISION
.....................................
75
8.9.
CONCLUSIONS
.....................................................................................................................................
75
YY
DECISION
MAKING
IN
THE
MANAGEMENT
OF
CHILDREN
WITH
ITP
80
9.1.
A
PREFERENCE-SENSITIVE
DECISION
....................................................................................................
80
9.2.
SHARED
DECISION
MAKING
.................................................................................................................
81
9.3.
CONCLUSION
......................................................................................................................................
81
ITP
IN
CHILDHOOD:
A
PROBLEM-ORIENTED
REVIEW
OF
THE
MANAGEMENT
84
10.1.
CLINICAL
PRESENTATION
AND
DIAGNOSIS
..............................................................................................
85
10.2.
PREVENTION
FROM
AND
THERAPY
OF
BLEEDING
....................................................................................
87
10.3.
NON-INTERVENTION
............................................................................................................................
88
10.4.
INTERVENTION
....................................................................................................................................
88
10.5.
SPLENECTOMY
..................................................................................................................................
90
10.6.
CONCLUSIONS
....................................................................................................................................
90
[J
ITP
IN
ADULTHOOD
93
11.1.
TREATMENT
OF
ADULT
ITP
...................................................................................................................
94
11.1.1.
GENERAL
RULES
.....................................................................................................................................
94
11.1.2.
FIRST-LINE
THERAPY
(INITIAL
TREATMENT
FOR
NEWLY
DIAGNOSED
PATIENTS)
...................................................
94
11.1.3.
SECOND-LINE
THERAPY
.........................................................................................................................
95
11.1.4.
OTHER
SECOND-LINE
THERAPIES
............................................................................................................
97
11.1.5.
PATIENTS
FAILING
MULTIPLE
THERAPIES
.....................................................................................................
99
11.1.6.
NEW SECOND
OR
THIRD
OR
LATER-LINE
THERAPIES
IN
THE
MANAGEMENT
OF
ADULTS
WITH
ITP
......................
100
11.2.
CONCLUSION
....................................................................................................................................
101
H
MANAGEMENT
OF
ITP
IN
THE
ELDERLY
105
12.1.
DIAGNOSIS
OF
ITP
IN
THE
ELDERLY
......................................................................................................
105
12.2.
TREATING
ITP
IN
THE
ELDERLY
............................................................................................................
105
12.2.1.
INTRAVENOUS
IMMUNOGLOBULINS
(MG)
..............................................................................................
106
12.2.2.
CORTICOSTEROIDS
................................................................................................................................
106
12.2.3.
MANAGING
TREATMENT
FAILURE
AND
CORTICOSTEROID
DEPENDENCY
.........................................................
106
12.2.4.
THROMBOPOIETIN
RECEPTOR
AGONISTS
................................................................................................
106
12.2.5.
RITUXIMAB
........................................................................................................................................
107
16
CONTENTS
12.2.6.
12.2.7.
12.2.8.
12.2.9.
13.1.
13.2.
13.3.
13.4.
13.5.
13.5.1.
13.5.1.1.
13.5.1.2.
13.5.1.3.
13.6.
13.7.
14.1.
14.2.
14.3.
15.2.
15.3.
15.4.
15.5.
15.6.
16.1.
16.2.
16.3.
16.4.
16.5.
16.6.
16.7.
16.8.
16.9.
FOSTAMATINIB
....................................................................................................................................
108
SPLENECTOMY
....................................................................................................................................
108
OTHER
MEDICATIONS
..........................................................................................................................
108
INVESTIGATIONAL
THERAPIES
................................................................................................................
108
CHRONIC
REFRACTORY
ITP
110
PRACTICAL
CONSIDERATIONS
OF
REFRACTORY
ITP
..................................................................................
110
INFECTION-RELATED
THROMBOCYTOPENIA
.........................................................................................
113
DRUG-INDUCED
THROMBOCYTOPENIA
..............................................................................................
115
SECONDARY
ITP
...............................................................................................................................
115
THERAPEUTIC
APPROACH
.................................................................................................................
116
GENERAL
APPROACH
TO
REFRACTORY
ITP
.................................................................................................
117
OBSERVATION
......................................................................................................................................
117
STANDARD
THERAPY
.............................................................................................................................
117
THERAPY
FOR
REFRACTORY
DISEASE
...........................................................................................................
117
OUTCOMES
AND
SEQUELAE
..............................................................................................................
121
SUMMARY
........................................................................................................................................
122
IMMUNE
THROMBOCYTOPENIA
IN
PREGNANCY
127
THE
DIFFERENTIAL
DIAGNOSIS
OF
THROMBOCYTOPENIA
DURING
PREGNANCY
.......................................
127
ITP
IN
PREGNANCY
............................................................................................................................
128
CONCLUSION
....................................................................................................................................
130
DRUGS
IN
ITP:
MECHANISMS
OF
ACTION
133
STEROIDS
.........................................................................................................................................
133
INTRAVENOUS
IMMUNOGLOBULIN
(MG)
...........................................................................................
134
ANTI-D
.............................................................................................................................................
134
RITUXIMAB
(ANTI-CD20)
.................................................................................................................
135
DRUGS
THAT
STIMULATE
PLATELET
PRODUCTION
..................................................................................
136
CONCLUSION
....................................................................................................................................
137
MECHANISM
OF
ACTION
OF
HIGH
DOSE
INTRAVENOUS
IMMUNOGLOBULIN
IN
ITP
141
INTRODUCTION
..................................................................................................................................
141
MONONUCLEAR
PHAGOCYTE
SYSTEM
(MPS)
BLOCKADE
....................................................................
142
ANTI-IDIOTYPE
ANTIBODIES
..............................................................................................................
144
IGG
FC
REGION
SIALYLATION
AND
THE
INHIBITORY
FC
RECEPTOR
(FCYRIIB)
............................................
145
CYTOKINE
MODULATION
...................................................................................................................
146
NEONATAL
FC
RECEPTOR
(FCRN).........................................................................................................
147
DENDRITIC
CELLS
(DCS)
AND
IMMUNOMODULATION
..........................................................................
148
CURRENT
AND
EMERGING
MG
ALTERNATIVES
AND
MIMETICS
FOR
USE
IN
ITP
.......................................
149
OTHER
MECHANISMS
AND
CONCLUSIONS
...........................................................................................
151
17.1.
17.2.
17.3.
17.4.
IMMUNE
THROMBOCYTOPENIA
-
THE
PATIENTS
PERSPECTIVE
158
PATIENTS
HATE
STEROIDS
................................................................................................................
158
RITUXIMAB
......................................................................................................................................
159
PATIENTS
TRY
TO
AVOID
SPLENECTOMY
..............................................................................................
159
PATIENTS
AND
THROMBOPOETIN-RECEPTOR
AGONISTS
(TRAS)..........................................................
159
CONTENTS
17
17.5.
OTHER
THERAPIES
.............................................................................................................................
160
17.6.
THE
QUAGMIRE
OF
MODERN
MEDICINE
.............................................................................................
160
17.7.
WHAT
PATIENTS
REALLY
WANT
............................................................................................................
162
17.8.
CONCLUSIONS
..................................................................................................................................
162
H
QUALITY
OF
LIFE
AS
A
TREATMENT
ENDPOINT
FOR
PATIENTS
WITH
ITP
164
18.1.
INTRODUCTION
....................................................................................................................................
164
18.2.
ASSESSMENT
OF
HEALTH
RELATED
QUALITY
OF
LIFE
IN
ITP
....................................................................
164
18.2.1.
HRQOL
IN
ADULTS
..............................................................................................................................
164
18.2.2.
HRQOL
IN
CHILDREN
...........................................................................................................................
165
18.3.
ITP
SYMPTOMS
IN
HRQOL
...............................................................................................................
165
18.3.1.
BLEEDING
AND
BRUISING
......................................................................................................................
166
18.3.2.
FATIGUE
.............................................................................................................................................
167
18.4.
IMPACT
OF
TREATMENTS
ON
HRQOL
..................................................................................................
167
18.4.1.
FIRST-LINE
AGENTS
................................................................................................................................
167
18.4.2.
SECOND-LINE
THERAPIES
......................................................................................................................
168
18.5.
CONCLUSION
.....................................................................................................................................
169
GJ|
FATIGUE
AS
A
TREATMENT
END
POINT
IN
ITP
172
19.1.
HOW
DO
WE
DEFINE
FATIGUE
.............................................................................................................
172
19.2.
HOW
CAN
WE
ASSESS
FATIGUE
...........................................................................................................
172
19.3.
HOW
MUCH
OF
A
PROBLEM
IS
FATIGUE
IN
ITP
.....................................................................................
173
19.4.
WHY
DOES
FATIGUE
DEVELOP
IN
ITP
................................................................................................
176
19.5.
CYTOKINES
AND
IMMUNE
DYSREGULATION
........................................................................................
177
19.6.
HOW
DO
WE
MANAGE
THE
ITP
PATIENT
WITH
FATIGUE
.......................................................................
179
19.7.
IMPROVING
THE
STANDARD
OF
CARE
..................................................................................................
180
19.8.
CONCLUSION
....................................................................................................................................
181
H
GUIDELINES
FOR
USING
ITP
MANAGEMENT
GUIDELINES
186
20.1.
GUIDELINES
FOR
MANAGEMENT
OF
ITP
..............................................................................................
187
20.2.
PROS
AND
CONS
OF
GUIDELINES
..........................................................................................................
187
20.3.
EVIDENCE
BASED
VS.
PATIENT
CENTERED
MANAGEMENT
....................................................................
188
QI
STATE
OF
THE
ART
AND
FUTURE
CONSIDERATIONS
OF
ITP
190
21.1.
HETEROGENEITY
OF
ITP
.....................................................................................................................
190
21.2.
UNKNOWN
ETIOLOGY
OF
ITP
...............................................................................................................
192
21.3.
IMMUNOMODULATION
IN
INFLAMMATORY
AND
AUTOIMMUNE
DISORDERS
..........................................
192
21.4.
PLATELET
STIMULATION
BY
THROMBOPOIETIN
RECEPTOR
AGONISTS
(TPO-RA)
OF
MEGAKARYOPOIESIS
.
193
21.5.
FUTURE
PROGRESS
AND
THE
QUESTION
OF
ADEQUATE
MANAGEMENT
OF
ITP
........................................
194
LIST
OF
ABBREVIATIONS
INDEX
201
203
|
| adam_txt |
14
CONTENTS
CONTENTS
INTRODUCTION
18
HISTORY
OF
ITP
21
2.1.
INTRODUCTION:
WHAT
IS
THROMBOCYTOPENIC
BLEEDING?
.
21
2.2.
HISTORY
OF
BLEEDING
.
22
2.3.
HISTORY
OF
THE
PATHOGENESIS
OF
ITP
.
23
2.4.
HISTORY
OF
MANAGEMENT
OF
PATIENTS
WITH
ITP
.
23
2.5.
THE
THERAPEUTIC
TRANSLATION
OF
MG
TO
OTHER
AUTOIMMUNE
DISORDERS
WITH
SIMILAR
PATHOPHYSIOLOGY
AS
IN
ITP
.
25
2.6.
STIMULATION
OF
PLATELET
PRODUCTION
BY
MEGAKARYOCYTES
.
26
2.7.
RECENT
DEVELOPMENT
OF
CLINICAL
RESEARCH
OF
ITP
AND
NEW
ASPECTS
OF
PLATELETS
THEMSELVES
.
27
BASIC
IMMUNOLOGY
OF
ITP
30
3.1.
T
CELL
AND
CYTOKINE ABNORMALITIES
IN
ITP
.
30
3.2.
B
CELL
ABNORMALITIES
.
31
3.3.
DENDRITIC
CELLS
(DC)
IN
ITP
.
31
3.4.
ENVIRONMENTAL
FACTORS
IN
ITP
.
32
3.5.
ALTERNATIVE
MODES
OF
THROMBOCYTOPENIA
IN
ITP
.
33
3.6.
CONCLUSIONS
.
33
JI
MEGAKARYOPOIESIS
IN
ITP
36
4.1.
OVERVIEW
OF
NORMAL
THROMBOPOIESIS
.
36
4.2.
THROMBOPOIESIS
IN
ITP:
EVIDENCE
FOR
ACCELERATED
PLATELET
DESTRUCTION
.
38
4.3.
THROMBOPOIESIS
IN
ITP:
EVIDENCE
FOR
IMPAIRED
PLATELET
PRODUCTION
.
39
4.4.
MEGAKARYOPOIESIS
IN
ITP:
EVIDENCE
FOR
DIRECT
ROLES
OF
MEGAKARYOCYTES
.40
GENETICS
OF
ITP
45
5.1.
CHALLENGES
IN
DEFINING
A
GENETIC
ETIOLOGY
OF
ITP
.
45
5.2.
GERMLINE
SINGLE-NUCLEOTIDE
VARIANT
(5NV)
CANDIDATE
GENE
APPROACH
.
45
5.3.
FAMILIAL
ITP
.
45
5.4.
GENOME-WIDE
ASSOCIATION
STUDIES
(GWAS)
.46
5.5.
FUTURE
DIRECTIONS
.
47
U
DIFFERENTIAL
DIAGNOSIS
OF
ITP:
INHERITED
THROMBOCYTOPENIAS 48
6.1.
INHERITED
THROMBOCYTOPENIAS
.48
6.1.1.
CLINICAL
AND
LABORATORY
PECULIARITIES
OF
INHERITED
THROMBOCYTOPENIAS
.
48
6.1.2.
WHEN
TO
SUSPECT
INHERITED
THROMBOCYTOPENIAS
.
54
6.2.
DIFFERENTIAL
DIAGNOSIS
BETWEEN
ITP
AND
INHERITED
THROMBOCYTOPENIAS
.
55
6.3.
HOW
TO
CONFIRM
THE
SUSPICION
OF
INHERITED
THROMBOCYTOPENIA
.
57
J|
SECONDARY
ITP
59
7.1.
DEFINITION
AND
LIMITATION
.
59
7.2.
ETIOLOGY
.
59
7.3.
DIAGNOSTIC
WORKFLOW
.
60
CONTENTS
15
7.4.
GENETIC
PANEL
.
62
7.5.
ADULT
VERSUS
CHILDREN
.
62
7.6.
CONCLUSIONS
.
64
STANDARDIZATION
OF
DEFINITIONS,
TERMINOLOGY
AND
OUTCOME
CRITERIA:
A
COMMON
LANGUAGE
IN
ITP
67
8.1.
CRITERIA
ADOPTED
BY
THE
IWG
TO
HARMONIZE
TERMINOLOGY
AND
DEFINITIONS
IN
ITP
.
68
8.2.
PRIMARY
AND
SECONDARY
ITP
AND
DIAGNOSTIC
PLATELET
COUNT
THRESHOLD
.
68
8.3.
DEFINITION
OF
THE
DIFFERENT
PHASES
AND
SEVERITY
OF
THE
DISEASE
.
69
8.4.
THERAPEUTIC
GOALS
.
70
8.5.
DEFINITION
OF
RESPONSE
.
71
8.6.
REFRACTORY
ITP:
DEFINITION,
THERAPEUTIC
GOALS
AND
RESPONSE
ASSESSMENT
.
73
8.7.
CLINICAL
TRIAL-ADAPTED
CRITERIA
FOR
ELIGIBILITY
AND
OUTCOME
ASSESSMENT
.
75
8.8.
APPLICATION
OF
2009
IWG
PROPOSALS
IN
REAL-WORD
AND
NEED
FOR
REVISION
.
75
8.9.
CONCLUSIONS
.
75
YY
DECISION
MAKING
IN
THE
MANAGEMENT
OF
CHILDREN
WITH
ITP
80
9.1.
A
PREFERENCE-SENSITIVE
DECISION
.
80
9.2.
SHARED
DECISION
MAKING
.
81
9.3.
CONCLUSION
.
81
ITP
IN
CHILDHOOD:
A
PROBLEM-ORIENTED
REVIEW
OF
THE
MANAGEMENT
84
10.1.
CLINICAL
PRESENTATION
AND
DIAGNOSIS
.
85
10.2.
PREVENTION
FROM
AND
THERAPY
OF
BLEEDING
.
87
10.3.
NON-INTERVENTION
.
88
10.4.
INTERVENTION
.
88
10.5.
SPLENECTOMY
.
90
10.6.
CONCLUSIONS
.
90
[J
ITP
IN
ADULTHOOD
93
11.1.
TREATMENT
OF
ADULT
ITP
.
94
11.1.1.
GENERAL
RULES
.
94
11.1.2.
FIRST-LINE
THERAPY
(INITIAL
TREATMENT
FOR
NEWLY
DIAGNOSED
PATIENTS)
.
94
11.1.3.
SECOND-LINE
THERAPY
.
95
11.1.4.
OTHER
SECOND-LINE
THERAPIES
.
97
11.1.5.
PATIENTS
FAILING
MULTIPLE
THERAPIES
.
99
11.1.6.
NEW SECOND
OR
THIRD
OR
LATER-LINE
THERAPIES
IN
THE
MANAGEMENT
OF
ADULTS
WITH
ITP
.
100
11.2.
CONCLUSION
.
101
H
MANAGEMENT
OF
ITP
IN
THE
ELDERLY
105
12.1.
DIAGNOSIS
OF
ITP
IN
THE
ELDERLY
.
105
12.2.
TREATING
ITP
IN
THE
ELDERLY
.
105
12.2.1.
INTRAVENOUS
IMMUNOGLOBULINS
(MG)
.
106
12.2.2.
CORTICOSTEROIDS
.
106
12.2.3.
MANAGING
TREATMENT
FAILURE
AND
CORTICOSTEROID
DEPENDENCY
.
106
12.2.4.
THROMBOPOIETIN
RECEPTOR
AGONISTS
.
106
12.2.5.
RITUXIMAB
.
107
16
CONTENTS
12.2.6.
12.2.7.
12.2.8.
12.2.9.
13.1.
13.2.
13.3.
13.4.
13.5.
13.5.1.
13.5.1.1.
13.5.1.2.
13.5.1.3.
13.6.
13.7.
14.1.
14.2.
14.3.
15.2.
15.3.
15.4.
15.5.
15.6.
16.1.
16.2.
16.3.
16.4.
16.5.
16.6.
16.7.
16.8.
16.9.
FOSTAMATINIB
.
108
SPLENECTOMY
.
108
OTHER
MEDICATIONS
.
108
INVESTIGATIONAL
THERAPIES
.
108
CHRONIC
REFRACTORY
ITP
110
PRACTICAL
CONSIDERATIONS
OF
REFRACTORY
ITP
.
110
INFECTION-RELATED
THROMBOCYTOPENIA
.
113
DRUG-INDUCED
THROMBOCYTOPENIA
.
115
SECONDARY
ITP
.
115
THERAPEUTIC
APPROACH
.
116
GENERAL
APPROACH
TO
REFRACTORY
ITP
.
117
OBSERVATION
.
117
STANDARD
THERAPY
.
117
THERAPY
FOR
REFRACTORY
DISEASE
.
117
OUTCOMES
AND
SEQUELAE
.
121
SUMMARY
.
122
IMMUNE
THROMBOCYTOPENIA
IN
PREGNANCY
127
THE
DIFFERENTIAL
DIAGNOSIS
OF
THROMBOCYTOPENIA
DURING
PREGNANCY
.
127
ITP
IN
PREGNANCY
.
128
CONCLUSION
.
130
DRUGS
IN
ITP:
MECHANISMS
OF
ACTION
133
STEROIDS
.
133
INTRAVENOUS
IMMUNOGLOBULIN
(MG)
.
134
ANTI-D
.
134
RITUXIMAB
(ANTI-CD20)
.
135
DRUGS
THAT
STIMULATE
PLATELET
PRODUCTION
.
136
CONCLUSION
.
137
MECHANISM
OF
ACTION
OF
HIGH
DOSE
INTRAVENOUS
IMMUNOGLOBULIN
IN
ITP
141
INTRODUCTION
.
141
MONONUCLEAR
PHAGOCYTE
SYSTEM
(MPS)
BLOCKADE
.
142
ANTI-IDIOTYPE
ANTIBODIES
.
144
IGG
FC
REGION
SIALYLATION
AND
THE
INHIBITORY
FC
RECEPTOR
(FCYRIIB)
.
145
CYTOKINE
MODULATION
.
146
NEONATAL
FC
RECEPTOR
(FCRN).
147
DENDRITIC
CELLS
(DCS)
AND
IMMUNOMODULATION
.
148
CURRENT
AND
EMERGING
MG
ALTERNATIVES
AND
MIMETICS
FOR
USE
IN
ITP
.
149
OTHER
MECHANISMS
AND
CONCLUSIONS
.
151
17.1.
17.2.
17.3.
17.4.
IMMUNE
THROMBOCYTOPENIA
-
THE
PATIENTS'
PERSPECTIVE
158
PATIENTS
"HATE
STEROIDS"
.
158
RITUXIMAB
.
159
PATIENTS
TRY
TO
AVOID
SPLENECTOMY
.
159
PATIENTS
AND
THROMBOPOETIN-RECEPTOR
AGONISTS
(TRAS).
159
CONTENTS
17
17.5.
OTHER
THERAPIES
.
160
17.6.
THE
QUAGMIRE
OF
MODERN
MEDICINE
.
160
17.7.
WHAT
PATIENTS
REALLY
WANT
.
162
17.8.
CONCLUSIONS
.
162
H
QUALITY
OF
LIFE
AS
A
TREATMENT
ENDPOINT
FOR
PATIENTS
WITH
ITP
164
18.1.
INTRODUCTION
.
164
18.2.
ASSESSMENT
OF
HEALTH
RELATED
QUALITY
OF
LIFE
IN
ITP
.
164
18.2.1.
HRQOL
IN
ADULTS
.
164
18.2.2.
HRQOL
IN
CHILDREN
.
165
18.3.
ITP
SYMPTOMS
IN
HRQOL
.
165
18.3.1.
BLEEDING
AND
BRUISING
.
166
18.3.2.
FATIGUE
.
167
18.4.
IMPACT
OF
TREATMENTS
ON
HRQOL
.
167
18.4.1.
FIRST-LINE
AGENTS
.
167
18.4.2.
SECOND-LINE
THERAPIES
.
168
18.5.
CONCLUSION
.
169
GJ|
FATIGUE
AS
A
TREATMENT
END
POINT
IN
ITP
172
19.1.
HOW
DO
WE
DEFINE
FATIGUE
.
172
19.2.
HOW
CAN
WE
ASSESS
FATIGUE
.
172
19.3.
HOW
MUCH
OF
A
PROBLEM
IS
FATIGUE
IN
ITP
.
173
19.4.
WHY
DOES
FATIGUE
DEVELOP
IN
ITP
.
176
19.5.
CYTOKINES
AND
IMMUNE
DYSREGULATION
.
177
19.6.
HOW
DO
WE
MANAGE
THE
ITP
PATIENT
WITH
FATIGUE
.
179
19.7.
IMPROVING
THE
STANDARD
OF
CARE
.
180
19.8.
CONCLUSION
.
181
H
GUIDELINES
FOR
USING
ITP
MANAGEMENT
GUIDELINES
186
20.1.
GUIDELINES
FOR
MANAGEMENT
OF
ITP
.
187
20.2.
PROS
AND
CONS
OF
GUIDELINES
.
187
20.3.
EVIDENCE
BASED
VS.
PATIENT
CENTERED
MANAGEMENT
.
188
QI
STATE
OF
THE
ART
AND
FUTURE
CONSIDERATIONS
OF
ITP
190
21.1.
HETEROGENEITY
OF
ITP
.
190
21.2.
UNKNOWN
ETIOLOGY
OF
ITP
.
192
21.3.
IMMUNOMODULATION
IN
INFLAMMATORY
AND
AUTOIMMUNE
DISORDERS
.
192
21.4.
PLATELET
STIMULATION
BY
THROMBOPOIETIN
RECEPTOR
AGONISTS
(TPO-RA)
OF
MEGAKARYOPOIESIS
.
193
21.5.
FUTURE
PROGRESS
AND
THE
QUESTION
OF
ADEQUATE
MANAGEMENT
OF
ITP
.
194
LIST
OF
ABBREVIATIONS
INDEX
201
203 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Kühne, Thomas |
| author_GND | (DE-588)1037169956 |
| author_facet | Kühne, Thomas |
| author_role | aut |
| author_sort | Kühne, Thomas |
| author_variant | t k tk |
| building | Verbundindex |
| bvnumber | BV048577021 |
| classification_rvk | YC 2922 |
| ctrlnum | (OCoLC)1319834906 (DE-599)DNB1258091410 |
| dewey-full | 616.15 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.15 |
| dewey-search | 616.15 |
| dewey-sort | 3616.15 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| edition | 3rd edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02157nam a2200517 c 4500</leader><controlfield tag="001">BV048577021</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">221123s2022 gw a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">22,N21</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">22,A27</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1258091410</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837416244</subfield><subfield code="c">Festeinband : EUR 44.80 (DE), EUR 46.10 (AT), CHF 74.00 (freier Preis)</subfield><subfield code="9">978-3-8374-1624-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3837416240</subfield><subfield code="9">3-8374-1624-0</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783837416244</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1319834906</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1258091410</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-HB</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.15</subfield><subfield code="2">23/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 2922</subfield><subfield code="0">(DE-625)153205:12928</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kühne, Thomas</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1037169956</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immune thrombocytopenia (ITP)</subfield><subfield code="c">Thomas Kühne ; in collaboration with Carlo L. Balduini [und 25 andere]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">3rd edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen ; London ; Boston</subfield><subfield code="b">UNI-MED Verlag AG</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">204 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">25 cm, 495 g</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Essenzielle Thrombozytopenie</subfield><subfield code="0">(DE-588)4070972-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immune Thrombocytopenia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ITP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">thrombocytopenic purpura</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immune Thrombocytopenia;TIP;thrombocytopenic purpura</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Essenzielle Thrombozytopenie</subfield><subfield code="0">(DE-588)4070972-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">UNI-MED Verlag AG</subfield><subfield code="0">(DE-588)1065561733</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="780" ind1="0" ind2="0"><subfield code="i">Vorangegangen ist</subfield><subfield code="z">9783837413960</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=5ef5396f02c440b3a3b82923702711f2&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">https://d-nb.info/1258091410/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033952989&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033952989</subfield></datafield></record></collection> |
| id | DE-604.BV048577021 |
| illustrated | Illustrated |
| index_date | 2024-07-03T21:03:39Z |
| indexdate | 2024-07-10T09:41:58Z |
| institution | BVB |
| institution_GND | (DE-588)1065561733 |
| isbn | 9783837416244 3837416240 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033952989 |
| oclc_num | 1319834906 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | 204 Seiten Illustrationen 25 cm, 495 g |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | UNI-MED Verlag AG |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Kühne, Thomas Verfasser (DE-588)1037169956 aut Immune thrombocytopenia (ITP) Thomas Kühne ; in collaboration with Carlo L. Balduini [und 25 andere] 3rd edition Bremen ; London ; Boston UNI-MED Verlag AG 2022 204 Seiten Illustrationen 25 cm, 495 g txt rdacontent n rdamedia nc rdacarrier UNI-MED science Essenzielle Thrombozytopenie (DE-588)4070972-3 gnd rswk-swf Immune Thrombocytopenia ITP thrombocytopenic purpura Immune Thrombocytopenia;TIP;thrombocytopenic purpura Essenzielle Thrombozytopenie (DE-588)4070972-3 s DE-604 UNI-MED Verlag AG (DE-588)1065561733 pbl Vorangegangen ist 9783837413960 X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=5ef5396f02c440b3a3b82923702711f2&prov=M&dok_var=1&dok_ext=htm Inhaltstext B:DE-101 application/pdf https://d-nb.info/1258091410/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033952989&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Kühne, Thomas Immune thrombocytopenia (ITP) Essenzielle Thrombozytopenie (DE-588)4070972-3 gnd |
| subject_GND | (DE-588)4070972-3 |
| title | Immune thrombocytopenia (ITP) |
| title_auth | Immune thrombocytopenia (ITP) |
| title_exact_search | Immune thrombocytopenia (ITP) |
| title_exact_search_txtP | Immune thrombocytopenia (ITP) |
| title_full | Immune thrombocytopenia (ITP) Thomas Kühne ; in collaboration with Carlo L. Balduini [und 25 andere] |
| title_fullStr | Immune thrombocytopenia (ITP) Thomas Kühne ; in collaboration with Carlo L. Balduini [und 25 andere] |
| title_full_unstemmed | Immune thrombocytopenia (ITP) Thomas Kühne ; in collaboration with Carlo L. Balduini [und 25 andere] |
| title_short | Immune thrombocytopenia (ITP) |
| title_sort | immune thrombocytopenia itp |
| topic | Essenzielle Thrombozytopenie (DE-588)4070972-3 gnd |
| topic_facet | Essenzielle Thrombozytopenie |
| url | http://deposit.dnb.de/cgi-bin/dokserv?id=5ef5396f02c440b3a3b82923702711f2&prov=M&dok_var=1&dok_ext=htm https://d-nb.info/1258091410/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033952989&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT kuhnethomas immunethrombocytopeniaitp AT unimedverlagag immunethrombocytopeniaitp |